Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Low Intensity Focused Ultrasound for Patients With Fibromyalgia

6. november 2026 oppdatert av: Patrick Finan, PhD, University of Virginia

Early Feasibility Study of Low Intensity Focused Ultrasound Neuromodulation in Patients With Fibromyalgia

The overall goal of this study is to establish the safety and feasibility of low intensity transcranial focused ultrasound (liFU) stimulation for patients with fibromyalgia. We will also attempt to investigate the efficacy of liFU for pain and related symptoms and to compare whether liFU effects differ for people trained in different types of meditation.

Studieoversikt

Detaljert beskrivelse

Following informed consent (Session 1), participants will participate in a baseline assessment (Session 2), during which they will receive a full battery of questionnaires, as well as a task-based fMRI and a baseline CT scan (the latter used for brain mapping in preparation of the liFU intervention). They will also be randomized during this session. The study is divided into two phases; in Phase 1 they will undergo four virtual sessions of a meditation intervention (either Savoring Meditation or Slow Breathing Meditation), depending on their group allocation (Session 3 to Session 6). They will then receive another assessment composed of questionnaires and a task-based fMRI (Session 7). In Phase 2 they will receive the liFU intervention (Session 8 to Session 11). At Session 11, they will also receive a post-treatment assessment composed of questionnaires and a task-based fMRI. A follow-up assessment (Session 12) four weeks after their final liFU intervention will be composed of questionnaires.

Studietype

Intervensjonell

Registrering (Antatt)

40

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

  • Navn: Claudia Denoue F Postdoctoral Researcher, M.D.
  • Telefonnummer: (434)-982-2281
  • E-post: finanlab@uvahealth.org

Studer Kontakt Backup

  • Navn: Sierra Clark Clinical Research Coordinator
  • Telefonnummer: (434)-982-2281
  • E-post: finanlab@uvahealth.org

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 75 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Hunn

Beskrivelse

Inclusion Criteria:

  • Females aged 18-75 years
  • Physician-confirmed diagnosis of FM according to the 2016 American College of Rheumatology criteria.
  • Willingness and ability to comply with scheduled visits and study procedures

Exclusion Criteria:

  • History of major neurological disorders
  • Current unstable psychiatric disorders or severe current substance use disorders
  • Current prescription opioid use or self -reported use of opioids in the past 30 days prior to enrollment (other medications are allowed, but must be on stable dose for at least 4 weeks)
  • Contraindications to MRI
  • Pregnancy or breastfeeding
  • Current neuromodulation therapy
  • Current meditation practice
  • Current participation in another interventional trial that could confound outcomes
  • Cannot read and speak English
  • Prisoner or cognitively impaired individuals
  • Unwilling or unable to use the internet and/or internet-enabled device to complete study procedures
  • Unable or unwilling to comply with study protocols or otherwise determined by the PI to be able to safely participate in the study.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Low Intensity Focused Ultrasound + Savoring Meditation (liFU+SM)

In this arm, participants first receive training in Savoring Meditation, a positive affect-focused behavioral intervention designed to enhance positive affect and support chronic pain self-management. Participants complete four 20-minute telehealth training sessions over approximately two weeks delivered by a trained interventionist. After completing the meditation training portion, participants in the liFU + SM arm complete four sessions of low-intensity focused ultrasound targeting the nucleus accumbens during which they actively practice Savoring Meditation concurrent with the sonication.

Andre navn:
  • liFU + SM
Aktiv komparator: Low Intensity Focused Ultrasound

In the liFU arm, participants first spend 4 telehealth sessions undergoing training in a slow breathing meditation practice. Subsequently, participants complete four in-person liFU treatment sessions over four weeks, with sequential bilateral sonications targeting the nucleus accumbens during each session. In this arm, participants do not engage in any concurrent meditation practice or other behavioral intervention during sonication. Rather, they only receive liFU sonication during those sessions.

Andre navn:
  • liFU

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Safety of liFU intervention
Tidsramme: At Session 7 (Week 3), at Sessions 8-11 (Weeks 3-6; immediately before and after each intervention and 24h after each intervention), weekly throughout weeks 7-11 and at Session 12 (Week 11).

Number of treatment-related unexpected adverse events and serious adverse events

At Session 7 (Week 3), at Sessions 8-11 (Weeks 3-6; immediately before and after each intervention and 24h after each intervention), weekly throughout weeks 7-11 and at Session 12 (Week 11).
Study recruitment rate
Tidsramme: Assessed from screening (Session 1; week -1) to enrollment (Session 2; week 0).

Number of participants enrolled divided by number screened.

Assessed from screening (Session 1; week -1) to enrollment (Session 2; week 0).
Study adherence
Tidsramme: Assessed from enrollment (Session 2; week 0) to follow up (Session 12; week 11).

Number of participants to complete all Phase 1 and Phase 2 intervention sessions

Assessed from enrollment (Session 2; week 0) to follow up (Session 12; week 11).
Study retention
Tidsramme: Assessed from enrollment (Session 2; week 0) to follow up (Session 12; week 11).

Number of enrolled participants retained through the entirety of the study

Assessed from enrollment (Session 2; week 0) to follow up (Session 12; week 11).

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Nucleus accumbens activation
Tidsramme: Assessed at Session 2 (week 0), Session 7 (week 3), and Session 11 (week 6).

Change in blood-oxygen-level-dependent (BOLD) signal in the nucleus accumbens, measured using functional MRI during a task that pairs meditation with noxious thermal stimulation, relative to rest. Changes will be compared between the liFU + Savoring Meditation and liFU arms.

Assessed at Session 2 (week 0), Session 7 (week 3), and Session 11 (week 6).
Change in nucleus accumbens-ventromedial prefrontal cortex functional connectivity
Tidsramme: Assessed at Session 2 (week 0), Session 7 (week 3), and Session 11 (week 6).

Change in functional connectivity between the nucleus accumbens (NAc) and ventromedial prefrontal cortex (vmPFC), measured using functional MRI during a task that pairs meditation with noxious thermal stimulation, relative to rest. Changes will be compared between the liFU + Savoring Meditation and liFU arms.

Assessed at Session 2 (week 0), Session 7 (week 3), and Session 11 (week 6).
Clinical pain impact
Tidsramme: Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).

Changes in clinical pain impact will be evaluated using the Pain, Enjoyment of life, and General activity (PEG) Scale, which is a hybrid measure of pain severity and pain interference. This scale is comprised of 3 items, each rated on a numerical scale from 0-10. The total score is averaged on a scale from 0-10.

Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).
Clinical pain severity
Tidsramme: Assessed at Session 2 (week 0), Session 7 (week 3), Sessions 8-11 (Weeks 3-6; immediately after each intervention and 24h after each intervention), weekly throughout weeks 7-11, and Session 12 (week 11).

Changes in clinical pain severity will be evaluated using the Brief Pain Inventory (BPI). Average pain in the past 24 hours is rated on a scale from 0-10.

Assessed at Session 2 (week 0), Session 7 (week 3), Sessions 8-11 (Weeks 3-6; immediately after each intervention and 24h after each intervention), weekly throughout weeks 7-11, and Session 12 (week 11).
Pain catastrophizing
Tidsramme: Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).

Changes in pain catastrophizing will be evaluated using the Pain Catastrophizing Scale (PCS). The PCS is a 13-item scale, each noted on a Likert like scale from 0-4. Total scores are obtained by summing all scores, to obtain a score between 0 and 52.

Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).
Fatigue
Tidsramme: Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).

Changes in fatigue levels will be evaluated using the Fatigue Severity Scale (FSS). The FSS is a 9-item scale, each noted on a Likert like scale from 1-7. Total scores are obtained by summing all scores, to obtain a score between 0 and 63.

Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).
Fibromyalgia Impact
Tidsramme: Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).

Fibromyalgia Impact will be assessed using the Fibromyalgia Impact Questionnaire Revised (FIQ-R). The FIQ-R is a 21-item scale where each item is rated on a scale from 0-10 and the overall score is calculated as the addition of all items and then normalized relative to a predefined level of importance for each item. Total scores range from 0-100.

Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).
Fibromyalgia Severity
Tidsramme: Assessed at Session 2 (week 0) and Session 7 (week 3).

Fibromyalgia Severity will be assessed with the Widespread Pain Index (WPI) and the Symptom Severity Scale (SSS). The WPI counts the number of tender points reported and can range from 0 to 19. The SSS assesses 3 items on a Likert-like scale (from 0-3) as well as 3 items on a binary Yes/No scale (Yes=1, No=0). The SSS scale yields a score ranging from 0-12. In total, the WPI-SSS score is calculated by adding the WPI and the SSS score, yielding a final total score ranging from 0-31.

Assessed at Session 2 (week 0) and Session 7 (week 3).
Sleep quality
Tidsramme: Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).

Sleep quality will be assessed using the Insomnia Severity Index (ISI) and the Pittsburgh Sleep Quality Index (PSQI). The ISI is a 7-item Likert-like scale (ranging from 0-4). The total score is obtained by adding all item scores, yielding a total possible range of 0-28. The PSQI is a scale comprising of 7 different components, each of which may range from 0-3. The total score is obtained by adding all component scores, yielding a total possible range of 0-21.

Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).
Positive Affect
Tidsramme: Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).

Changes in Positive Affect will be assessed using the Positive and Negative Affect Schedule - Expanded Form (PANAS-X). The PANAS-X consists of 60 items rated on a Likert-like scale (ranging from 1-5). Total scores are separated as General negative affective scores (ranging 10-50), General Positive Affective Scores (ranging 10-50) and a series of emotional scales with varying ranges.

Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).
Hedonic Capacity
Tidsramme: Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).

The Snaith-Hamilton Pleasure Scale (SHAPS) is a 14-item scale where each item is rated on a Likert-like scale ranging from 0-3. Total scores are obtained by adding each item, yielding a total score ranging from 0-42.

Assessed at Session 2 (week 0), Session 7 (week 3), and Session 12 (week 11).

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Samarbeidspartnere

Etterforskere

  • Hovedetterforsker: Patrick Finan Finan, PhD, Department of Anesthesiology, University of Virginia

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

15. januar 2027

Primær fullføring (Antatt)

15. januar 2029

Studiet fullført (Antatt)

1. april 2029

Datoer for studieregistrering

Først innsendt

3. november 2026

Først innsendt som oppfylte QC-kriteriene

6. november 2026

Først lagt ut (Faktiske)

13. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

13. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

6. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere